Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma.

Hyery KimHee Mang YoonEun Key KimYoung Shin RaHyo-Won KimMi-Sun YumMin-Jee KimJae Suk BaekYu Sub SungSang Min LeeHyeong-Seok LimByung Joo LeeHyun Taek LimDohyung KimJihee YoonHyunwoo BaeSoojin HwangYun-Ha ChoiKyung Ah KimIn Hee ChoiSeung Won LeeSu-Jung ParkBeom-Hee Lee

Published in: Neuro-oncology (2024)

Selumetinib decrease PN volume in the majority of pediatric and adult NF1 patients while also showing efficacy in non-malignant diverse NF1 manifestations.

Keyphrases

signaling pathway
end stage renal disease
lps induced
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
pi k akt
nuclear factor
childhood cancer
immune response
toll like receptor